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Genome Scan for Familial Abdominal Aortic Aneurysm
Using Sex and Family History as Covariates Suggests
Genetic Heterogeneity and Identifies Linkage to
Chromosome 19q13
Hidenori Shibamura, MD, PhD; Jane M. Olson, PhD; Clarissa van Vlijmen-van Keulen, MD;
Sarah G. Buxbaum, PhD; Doreen M. Dudek, MS; Gerard Tromp, PhD; Toru Ogata, MD;
Magdalena Skunca, MS; Natzi Sakalihasan, MD, PhD; Gerard Pals, PhD; Raymond Limet, MD, PhD;
Gerald L. MacKean, MD; Olivier Defawe, MS; Alain Verloes, MD; Claudette Arthur, BN, MBA;
Alan G. Lossing, MD; Marjorie Burnett, BS; Taijiro Sueda, MD, PhD; Helena Kuivaniemi, MD, PhD
Background—Abdominal aortic aneurysm (AAA) is a relatively common disease, with 1% to 2% of the population
harboring aneurysms. Genetic risk factors are likely to contribute to the development of AAAs, although no such risk
factors have been identified.
Methods and Results—We performed a whole-genome scan of AAA using affected-relative-pair (ARP) linkage analysis
that includes covariates to allow for genetic heterogeneity. We found strong evidence of linkage (logarithm of odds
[LOD] score4.64) to a region near marker D19S433 at 51.88 centimorgans (cM) on chromosome 19 with 36 families
(75 ARPs) when including sex and the number of affected first-degree relatives of the proband (Naff) as covariates. We
then genotyped 83 additional families for the same markers and typed additional markers for all families and obtained
a LOD score of 4.75 (P0.00014) with sex, Naff, and their interaction as covariates near marker D19S416 (58.69 cM).
We also identified a region on chromosome 4 with a LOD score of 3.73 (P0.0012) near marker D4S1644 using the
same covariate model as for chromosome 19.
Conclusions—Our results provide evidence for genetic heterogeneity and the presence of susceptibility loci for AAA on
chromosomes 19q13 and 4q31. (Circulation. 2004;109:2103-2108.)
Key Words: aorta  aneurysm  genetics  mapping
Approximately 15% of patients with abdominal aortic aneu-rysms (AAAs) and without any recognizable connective tissue
disorder, such as Ehlers-Danlos syndrome or Marfan syndrome,
have a positive family history for AAA.1 Two segregation studies
favored a genetic model in explaining the familial aggregation of
AAA and suggested the presence of a major gene effect.2,3 Finding
a susceptibility gene for AAA could lead to a simple DNA test to
identify individuals at risk for developing an AAA. Such a test
could be extremely useful because surgery for unruptured AAA is
highly successful, with low mortality and morbidity.4 However,
diagnosing AAAs is difficult because most AAAs are asymptom-
atic before their rupture, and population-based ultrasonography
screening to detect AAAs is not used routinely.
The aim of the present study was to find susceptibility loci
for AAA with the use of linkage analysis with covariates to
allow for locus heterogeneity.5–7 We used affected-relative-
pair (ARP) linkage analyses, methods recognized as useful
for identifying genes in complex genetic diseases.8 Addition-
ally, we chose the 2-phase/2-stage design for cost-
effectiveness and for minimizing the effort required in geno-
typing while maintaining statistical power to detect linkage.9
Methods
Subjects and Phenotyping
Families with at least 2 members with AAA10 were identified; details
on the family collection have been reported previously11 and are
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summarized in Table 1. An accepted definition of arterial aneu-
rysm10 was used.12–14 Patients were identified from surgery records
at vascular surgery units and were then contacted; consent was
obtained, and family histories were collected. A certified vascular
surgeon led the effort to identify AAA patients and affected family
members. Family histories of any new patients presenting for
surgical repair of AAAs at these sites were obtained in interviews
conducted by a research nurse specifically trained for this work. In
most cases, only a limited amount of information was available from
relatives of second degree or greater. A specific questionnaire
assessing skin and skeletal manifestations characteristic of Ehlers-
Danlos syndrome type IV or Marfan syndrome was used to identify
individuals with these disorders. Families with these disorders were
excluded from the study. Whenever possible, the AAA diagnosis of
a deceased family member was verified by requesting autopsy or
medical records. Some family members, if aged 50 years, were
examined by ultrasonography and were identified as affected if the
infrarenal aortic diameter was 3.0 cm, a cutoff point used previ-
ously.14 Occurrences of isolated iliac artery or other aneurysms (such
as thoracic or thoracoabdominal) were noted but were not included
in the study. All families were white: 42 Canadian, 36 Dutch, 23
Belgian, 10 American, 3 British, 3 Finnish, 1 Italian, and 1 Swedish.
The study was approved by the institutional review boards of Wayne
State University School of Medicine and each patient recruiting
center,11 and the subjects gave informed consent.
Design for DNA Linkage Study
We used an ARP design because the mode of inheritance of AAA is
unknown and because an unaffected individual may develop an AAA
subsequently or carry the susceptibility gene with incomplete pen-
etrance. A 2-phase/2-stage design for DNA linkage analysis was
chosen,9 in which a 10- to 15-centimorgan (cM) genome scan is
performed on a relatively small number of ARPs (stage 1 of phase I),
followed by typing of additional markers in regions detected in stage
1 (stage 2 of phase I), and finally followed by additional typing of
new ARPs (phase II) in all positive regions obtained in the first
phase. For the combined data set of 213 affected sibling pairs (ASPs)
and 22 other ARPs from 119 families (groups 1 and 2; Table 1), we
had at least 95% power to detect “significant linkage” (logarithm of
odds [LOD] score of 3.6)15 for a locus with a locus-specific relative
risk of 2.3 in the absence of locus heterogeneity.
Genotyping
We isolated genomic DNA from peripheral blood using a Puregene
kit (Gentra Systems, Inc). A whole-genome scan was performed by
the Mammalian Genotyping Service with the use of screening set 10
with 405 highly polymorphic microsatellite markers and an average
marker-to-marker distance of 10 cM.16 Additional microsatellite
markers on chromosome 19 were genotyped as described previous-
ly.17 Before genotyping polymerase chain reactions were performed,
a whole-genome amplification was carried out to increase the
amount of template DNA available for genotyping and to ensure that
limited resources were used cost-effectively.18 Additional genotyp-
ing on chromosomes 3, 4, 5, 6, 9, 14, and 21 after the whole-genome
scan was performed by deCODE Genetics Inc. A slightly smaller
number (116 ARPs) of samples were genotyped in group 2 for these
chromosomes compared with the number of samples genotyped for
chromosome 19 (157 ARPs) in our own laboratory, where new ARPs
were included into the study continuously. In addition, 2 new ASPs
and 1 other new ARP were identified in group 1 families while the
study was in progress, and they were included in chromosome 19
analyses.
Statistical Analyses
The genotype data were analyzed for genetic linkage with the
multipoint model-free ARP LOD score analysis with the use of the
computer program LODPAL from S.A.G.E. (version 4.2).19 To
allow for covariate-related locus heterogeneity, we applied a
covariate-based ARP LOD score method.6 The model is a 1-param-
eter modification of the conditional logistic parameterization of the
ASP LOD score introduced by Olson.6 An optimal mode of inheri-
tance parameter20 is specified that allows one to fit only a single
additional parameter per covariate. The model is parameterized in
TABLE 1. Characteristics of AAA Families
Category Group 1 Group 2 Total
No. of families 36 83 119
Average No. of affected individuals per family (range) 3.4(2–7) 3.1(2–7) 3.2(2–7)
Families with at least 4 affected first-degree relatives (%) 9 (25) 29 (35) 38 (32)
No. of affected individuals genotyped (male) 86 (75) 195 (155) 281 (230)
Status of AAA in
Individuals genotyped (male)
Elective surgery 67 (61) 131 (104) 198 (165)
Rupture 8 (7) 11 (11) 19 (18)
Detected by ultrasonography 11 (7) 53 (40) 64 (47)
Other affected individuals not genotyped (male)*
Elective surgery 12 (11) 24 (20) 36 (31)
Rupture 10 (8) 17 (14) 27 (22)
Detected by ultrasonography 2 (1) 10 (6) 12 (7)
Unconfirmed 5 (3) 7 (4) 12 (7)
Unaffected individuals genotyped (male) 52 (20) 67 (26) 119 (46)
ASPs genotyped 62 151 213
Other ARPs genotyped 13 9 22
Total ARPs in study 75 160 235
*There were a total of 87 (29 in group 1 and 58 in group 2) affected first-degree relatives who were
known to have AAA but from whom no sample was available because of death before the start of the
study (n73) or unwillingness to provide a sample (n14). In 5 and 7 such cases in groups 1 and
2, respectively, information about details of AAA was not available.
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terms of offspring recurrence risk ratio (1), conditional on K
covariates xk, as follows
(1) 1(x)exp(Kk1k xk),
where  is a parameter that measures the “average” linkage in the
sample, and the k are covariate-specific parameters that measure
the change in linkage as a function of the covariates and in terms
of the recurrence risk ratio for monozygotic twins (2), condi-
tional on K covariates xk, as follows
(2) 2(x)3.6341(x)2.634.
To simplify specification of constraints on parameter estimates, to
improve numerical stability, and so that  reflects average allele
sharing, all covariates are centered around their sample mean before
inclusion. In general, the values of  and k depend on the choice of
“coding scheme” for the covariates; a linear transformation of the
covariate changes neither the LOD score nor the estimates of
covariate-specific recurrence risk ratios. More importantly, conclu-
sions about the existence of locus heterogeneity and the extent or
nature of locus heterogeneity do not depend on the estimated value
of  (which may equal zero).
Asymptotic distributions of the resulting likelihood ratio tests
were used to obtain probability values.6 We report as LOD scores the
likelihood ratio statistics (LRSs) divided by 4.605 (ie, 2loge10).
Critical values for the LRSs were obtained as follows. The distribu-
tion of the LRS for the basic 1-parameter model is a 50:50 mixture
of a point mass at zero and a 2 distribution with 1 df. Addition of K
covariates gives an LRS with a distribution that is a 50:50 mixture of
a 2 with K df and a 2 with K1 df. The difference in LRS between
nested models that differ by J covariates has a 2 distribution with J
df. One can therefore test both the significance of the contribution of
a covariate and the overall evidence for linkage. The overall
evidence for linkage includes information about both the “average”
linkage for the sample and the change in linkage as a function of the
covariate.
Results
A whole-genome scan was performed with 36 AAA families,
including 62 ASPs and 13 other ARPs (group 1; Table 1). We
performed a model-free multipoint linkage analysis and
identified 4 regions, on chromosomes 3, 4, 6, and 21, as
significant at the 0.05 level (baseline values in Table 2).
We then extended the analyses to include sex and number of
affected first-degree relatives of the proband (Naff) as covari-
ates, and a total of 12 regions on chromosomes 3, 4, 5, 6, 9,
14, 19, and 21 were identified with a covariate effect
TABLE 2. Group 1 and 2 LOD Scores for Baseline and Covariate Models for
Regions With Largest LOD Scores for Group 1
Group Chromosome
Map
Position,* cM Flanking Markers
Multipoint LOD Score
Baseline† SexNaff‡
1 3 94 D3S3644–27666CA8.D§ 0.94 2.60¶
2 3 98 27486CA1§ 0.00 1.17
1 3 178 D3S3523–D3S1574 0.00 3.55¶
2 3 169 D3S3523–D3S1574 0.10 0.42
1 4 28 D4S403–D4S1567 0.10 2.86¶
2 4 16 D4S394 0.00 0.79
1 4 73 D4S3248–D4S2432 0.63 3.00¶
2 4 68 D4S3355–D4S2978 0.35 3.20¶
1 4 144 D4S1644–D4S1586 0.54 4.45¶
2 4 132 D4S2959 0.00 3.03¶
1 5 144 D5S1983–D5S2011 0.00 3.30¶
2 5 141 D5S1983 0.72 1.14
1 5 183 D5S211–D5S2008 0.01 2.86¶
2 5 190 D5S211–D5S2008 0.00 0.28
1 6 187 D6S1719–D6S1027 0.61 4.22¶
2 6 186 D6S1719–D6S1027 0.36 0.43
1 9 121 D9S930–D9S177 0.00 5.83¶
2 9 126 D9S177–D9S2145 0.00 0.84
1 14 72 D14S63–DG14S37§ 0.00 2.66¶
2 14 75 DG14S37§–D14S588 0.00 0.68
1 19 50 D19S931–D19SS433 0.00 4.64¶
2 19 59 D19S245–D19S587 0.00 1.22
1 21 21 D21S1257–D21S2052 0.88 2.45¶
2 21 21 D21S1257–D21S2052 0.00 0.61
*Indicates position of peak LOD score based on Marshfield genetic map.16
Multipoint LOD score analyzed †without covariates or ‡with sex and Naff as covariates.
§These markers are from deCODE marker set.
P0.05.
¶P0.01.
Shibamura et al Linkage of Familial AAA to 19q13 2105
 at UNIV MEDECINE LEIG 228272 on March 13, 2012http://circ.ahajournals.org/Downloaded from 
significant at the 0.01 level, suggesting the presence of
genetic heterogeneity (Table 2).
Twelve regions that were significant in the whole-genome
scan were selected for a follow-up study, and additional
microsatellite markers were genotyped in the 36 families and
in 83 new AAA families that included 151 ASPs and 9 other
ARPs (groups 1 and 2; Table 1). Three loci (68 and 132 cM
on chromosome 4, and 141 cM on chromosome 5) showed
some evidence of linkage in group 2 (Table 2), and these
regions were selected for detailed analyses (Table 3). Table 3
shows the LOD scores and parameter estimates for groups 1
and 2 as well as the total sample at the location that gave the
highest LOD score for the total sample. In the combined
analysis with groups 1 and 2 together, the locus on chromo-
some 5 did not appear significant (Table 3). The region at 140
cM on chromosome 4 had a LOD score of 3.73 (P0.0012)
(Table 3). The 70-cM region had a peak LOD score of 3.13
(P0.0042), although the parameter estimates were unstable
(not shown), and we therefore report the LOD score of 2.41,
which was 4 cM away from the peak, to be able to give more
accurate parameter estimates (Table 3).
The chromosome 19 region was also analyzed further
because (1) it had the second highest LOD score in the
original genome scan (Table 2); (2) we have recently identi-
fied a putative locus for intracranial aneurysms on chromo-
some 1917; and (3) it contains a large number of biologically
TABLE 4. Multiple Regression Analysis of Chromosome 19 at 58.69 cM (D19S416)
Model
Group 1
(64 ASPs, 78 Total ARPs)*
Group 2
(149 ASPs, 157 Total ARPs)*
Total Sample













 1, 2,     1, 2,     1, 2,   
Baseline 0.00    0.00    0.00    0.00    0.00    0.00   
Sex 0.45    0.00 0.36 0.00    0.00 0.01 0.07    0.00 0.06
 Naff 3.30‡§ 0.00030 0.00 0.40 0.23    0.00 0.07 1.22‡ 0.039 0.00 0.11
SexNaff 3.61 0.00054 0.00 0.08, 0.48 0.46    0.00 0.18, 0.12 1.74 0.032 0.00 0.18, 0.14
SexNaffsex*Naff 4.38 0.00031 0.06 0.41,0.30, 0.46 4.12‡§ 0.00054 0.00 0.14,0.35, 0.30 4.75‡§ 0.00014 0.00 0.14,0.30, 0.29
*No. of ARPs genotyped for chromosome 19 was larger than that analyzed for the other chromosomes (for details, see Methods). For definition of other footnotes,
see Table 3.
TABLE 3. Multiple Regression Analysis of Chromosome 4 and 5 Regions
Model*
Group 1
(62 ASPs, 75 Total ARPs)
Group 2
(106 ASPs, 116 Total ARPs)
Total Sample













 1, 2,     1, 2,     1, 2,   
Chromosome 4 at 70 cM (D4S2978)
Baseline 0.24    0.15    0.35    0.11    0.73 0.0334 0.13   
Sex 0.39    0.12 0.31 0.85    0.17 0.29 0.96    0.16 0.17
 Naff 0.39    0.20 0.11 1.80§ 0.0099 0.40 0.42 1.41 0.0249 0.18 0.12
SexNaff 0.82    0.35 1.03,0.23 3.20‡§ 0.0013 0.71 0.21, 0.67 1.65 0.0387 0.21 0.17, 0.12
SexNaffsex*Naff 3.75‡§ 0.0012 0.26 0.27, 1.24,0.73 3.74 0.0012 1.43 2.28,1.39, 1.31 2.41‡§ 0.018 1.17 2.64,1.51, 1.35
Chromosome 4 at 140 cM (D4S1644)
Baseline 0.63 0.0443 0.28    0.00    0.00    0.00    0.00   
Sex 0.81    0.28 0.49 2.40‡§ 0.0024 0.00 0.40 3.04‡§ 0.00055 0.04 0.41
Naff 0.81    0.35 0.12 0.01    0.00 0.01 0.12    0.00 0.04
SexNaff 1.59‡§ 0.0440 0.42 0.85,0.17 2.55 0.0056 0.00 0.42, 0.02 3.35 0.00097 0.05 0.43,0.03
SexNaffsex*Naff 1.69    0.33 0.09, 0.45,0.35 2.74 0.0094 0.00 0.46,0.05, 0.03 3.73 0.0012 0.11 0.54,0.20, 0.09
Chromosome 5 at 140cM (D5S816)
Baseline 0.00    0.00    0.72‡§ 0.0343 0.17    0.23    0.08   
Sex 0.09    0.00 0.27 1.11    0.20 0.18 0.35    0.09 0.09
Naff 1.44‡§ 0.0232 0.05 0.39 0.76    0.18 0.03 0.40    0.09 0.05
SexNaff 2.49‡§ 0.0063 0.29 0.33, 0.60 1.14    0.20 0.18, 0.03 0.50    0.09 0.08, 0.05
SexNaffsex*Naff 2.36 0.203 0.20 0.21, 0.62,0.05 1.45    0.23 0.15, 0.24,0.10 1.02    0.12 0.06, 0.25,0.11
*Linkage analysis models: baseline, without covariates; sex, sex as a covariate; Naff, No. of affected first-degree relatives of probands as a covariate; sexNaff, sex
and Naff as a covariate; sexNaff  sex * Naff, sex and Naff and their interactions as a covariate.
†P for overall linkage effect (average and covariate-related), if P0.05.
‡Most parsimonious model.
§Significant covariate effect compared with nearest nested model.
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plausible candidate genes.21 The highest LOD score on
chromosome 19 for group 2 was 4.12 (P0.00054) near
D19S416 and 58.69 cM from the p-terminus when sex, Naff,
and their interaction were used as covariates (Table 4). In the
combined analysis with groups 1 and 2, including 213 ASPs
and 22 other ARPs, the maximum LOD score was 4.75
(P0.00014) at 58 cM, just proximal to D19S416, with sex,
Naff, and their interaction as covariates (Table 4). The inter-
action term (sex*Naff) was significant in the total sample
(P0.00317) as well as in the 2 subsamples. These results
suggested that female-female pairs from families with larger
numbers of affected persons are most at risk from this locus,
although this locus also gives substantial risk to male-male
pairs from families with fewer affected persons. Both groups
1 and 2 had the peak LOD score at same location on
chromosome 19 (Figure). The best, most parsimonious model
was the one with Naff as a covariate in group 1 and a model
using sex, Naff, and their interaction as covariates in group 2
(Table 4).
Discussion
We found no evidence of linkage unless sex and number of
affected persons were included as covariates in the linkage
model. How then should our results be interpreted? As Dizier
and coworkers22 have shown, absence of a linkage signal can
be due to a factor on which the siblings differ, such as a
characteristic of the disease (eg, severity), or an environmen-
tal factor. For common diseases that are genetically complex,
such situations may be the rule rather than the exception.5–7
By allowing for heterogeneity in the analysis by including
covariates chosen a priori, we avoid these concerns and are
able to detect linkage signals obscured by the presence of
heterogeneity.
No prior DNA linkage studies with AAA exist, although 3
studies investigated familial thoracic aortic aneurysms and
dissections (TAAD) and identified linked loci on 5q,23 11q,24
and 3p24–25.25 Because our collection of AAA families
excluded patients with TAAD11 and the AAA loci do not
overlap with the TAAD loci, different genetic risk factors are
probably involved in the development of TAAD and AAA.
There are several plausible candidate genes in the 2 regions
with the highest LOD scores, such as IL15 (interleukin 15; a
plausible candidate gene with respect to inflammation in
AAA), GAB1 (GRB2-associated binding protein 1; an impor-
tant mediator of branching tubulogenesis and a central protein
in cellular growth response, transformation, and apoptosis),
and EDNRA (endothelin receptor type A; an endothelin-1
receptor expressed in many human tissues with the highest
level in the aorta) around 140 cM on chromosome 4, as well
as LRP3 (LDL receptor–related protein 3), HPN (transmem-
brane protease, serine 1; a serine-type peptidase involved in
cell growth and maintenance), PDCD5 (programmed cell
death 5; a protein expressed in tumor cells during apoptosis
independent of the apoptosis-inducing stimuli), and PEPD
(peptidase D; an Xaa-Pro dipeptidase important in collagen
catabolism) on chromosome 19.21,26 LRP3 is particularly
interesting because conditional knockout mice for LRP1,
another member of the gene family, developed arterial
aneurysms and atherosclerosis.27
It is likely that additional AAA loci will be identified by
testing other possible covariates, such as smoking, hyperten-
sion, and coronary artery disease, which was not possible in
this study because these risk factors are so common both in
the general population and in patients with AAA that the
relatively small number of families in this study did not
provide enough power to study them.
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